Home Cart Sign in  
Chemical Structure| 2591-17-5 Chemical Structure| 2591-17-5

Structure of D-Luciferin
CAS No.: 2591-17-5

Chemical Structure| 2591-17-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

D-luciferin is a substrate for firefly luciferase with a Km ~2 μM.

Synonyms: Firefly luciferin; Beetle Luciferin; D-(-)-Luciferin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of D-Luciferin

CAS No. :2591-17-5
Formula : C11H8N2O3S2
M.W : 280.32
SMILES Code : O=C([C@@H]1N=C(C2=NC3=CC=C(O)C=C3S2)SC1)O
Synonyms :
Firefly luciferin; Beetle Luciferin; D-(-)-Luciferin
MDL No. :MFCD00042929
InChI Key :BJGNCJDXODQBOB-SSDOTTSWSA-N
Pubchem ID :92934

Safety of D-Luciferin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CHO cells <30 μM Compared aminoluciferins with D-Luciferin in live cells, finding that most aminoluciferins yield higher flux than D-Luciferin at low concentrations. PMC4183640
CHO cells 250 μM At high concentrations, the relative emission from D-Luciferin is still equaled or exceeded by certain aminoluciferins (e.g., CycLuc1, CycLuc10, and CycLuc12). PMC4183640
L. infantum LLM-2346PpyRE9 promastigotes 250 µM to 0.25 µM Comparison of different substrates for parasite detection in vitro, CycLuc1 demonstrated a higher luminescent signal than D-luciferin and AkaLumine-HCl. PMC9781651
L. major JISH118PpyRE9 promastigotes 250 µM to 0.25 µM Comparison of different substrates for parasite detection in vitro, CycLuc1 demonstrated a higher luminescent signal than D-luciferin and AkaLumine-HCl. PMC9781651
T. brucei brucei AnTAR1PpyRE9 parasites 250 µM to 0.25 µM Comparison of different substrates for parasite detection in vitro, CycLuc1 demonstrated a higher luminescent signal than D-luciferin and AkaLumine-HCl. PMC9781651
L. infantum LLM-2346PpyRE9 promastigotes 250 µM to 2.5 µM CycLuc1 demonstrated a higher luminescent signal than D-luciferin and AkaLumine-HCl in vitro parasite detection. PMC9781651
L. major JISH118PpyRE9 promastigotes 250 µM to 2.5 µM CycLuc1 showed a higher luminescent signal than D-luciferin and AkaLumine-HCl at the highest concentration tested against L. major promastigotes. PMC9781651
T. brucei brucei AnTAR1.1PpyRE9 parasites 250 µM to 2.5 µM CycLuc1 showed a higher luminescent signal than D-luciferin and AkaLumine-HCl at the highest concentration tested against T. brucei. PMC9781651
T. brucei brucei AnTAR1PpyRE9 parasites 250 µM to 2.5 µM CycLuc1 demonstrated a higher luminescent signal than D-luciferin and AkaLumine-HCl in vitro. PMC9781651

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice BALB/c mice Intraperitoneal injection 48 mg DTG/kg food Once daily for 17 weeks D-Luciferin performs well in vivo imaging but has low uptake in some organs such as the brain. PMC4026177
Mice Brain striatum Intraperitoneal injection DTG (1.25 mg/kg), FTC (25 mg/kg), TFV (10 mg/kg) continuous 2 weeks, once daily Evaluate the performance of mutant luciferases in the brains of live mice, finding significantly reduced signal with D-Luciferin PMC4972182
Mice Healthy mice Intraperitoneal injection 25 mg/kg/day or 50 mg/kg/day Once daily for 7 days To measure luciferase activity, results showed that the bioluminescent signal in the colon was 11-fold higher when combined with ultrasound compared to mRNA alone. PMC5368009
BALB/c and Swiss mice Natural infection models of leishmaniasis and African trypanosomiasis Intraperitoneal injection 1 μg/ml Two immunizations, 10 days apart Comparison of different substrates for parasite detection in vivo, CycLuc1 showed similar efficacy at a 20-fold lower dose than D-luciferin. PMC9781651
mice BALB/c mice, FVB mice, C57BL/6 mice intraperitoneal injection 20 mg/kg/d Once daily for 3 days To evaluate the bioluminescence imaging effect of D-Luciferin in vivo, the results showed that D-Luciferin performs well in vivo, but its uptake in some organs such as the brain is low. PMC4026177
Mice Brain striatum Intraperitoneal injection 20 mg/kg Daily for three weeks Evaluate the performance of mutant luciferases in vivo, found that D-Luciferin signal was dramatically reduced PMC4972182
Mice Healthy mice Intraperitoneal injection 150 mg/kg single injection Measure luciferase expression PMC5368009
BALB/c and Swiss mice Leishmaniasis and African trypanosomiasis models Intraperitoneal injection 0.2 mL; 10 mg/mL Single injection CycLuc1 showed comparable efficacy to D-luciferin at a 20-fold lower dose, suitable for longitudinal follow-up in models of leishmaniasis and African trypanosomiasis. PMC9781651
Mice 4T1-luc2 breast cancer model, DB7-luc breast cancer model, CMT-64 lung cancer model, L2G85-FVB transgenic mice, AAV9-CMV-luc2 brain striatum model, Dat-Cre+/− Rosa26-luc+/− mice Intraperitoneal injection 5 mg/kg Once daily for two weeks Evaluate the bioluminescence imaging effect of D-Luciferin in various mouse models, results showed that D-Luciferin performed poorly in brain imaging and could not detect luciferase expression in deep brain tissues. PMC4026177
Mice Healthy mice and DSS-induced colitis mice Intraperitoneal injection 3 mg/kg twice a day for 4 weeks To evaluate mRNA expression in the colon, results showed that ultrasound-mediated mRNA delivery significantly increased luciferase expression. PMC5368009
Mice Brain striatum Intraperitoneal injection 150 mg/kg Single injection, imaging duration up to 60 minutes post-injection To evaluate the performance of these three luciferase mutants in vivo, each codon-optimized mutant was cloned into an adeno-associated viral (AA V) plasmid under the control of a CMV promoter, and packaged into AA V9 vectors. The AA V9-luciferase viruses were then used to transduce FVB mice in the brain striatum. Unlike the use of luciferase-expressing tumor cells, this viral gene delivery method allows luciferase expression in endogenous mouse cells, for the life of the mouse (well over a year). As we have previously described for AA V9 transduction with the WT luciferase, each luciferase-expressing mouse was imaged after i.p. injection with a phosphate-buffered saline (PBS) solution of each luciferin. These experiments were performed in the exact same set of mice, imaged with each substrate on sequential days. For all of the mutant luciferases, brain bioluminescence was dramatically reduced when using D-luciferin compared to CycLuc1 and CycLuc2 (Figure 3). With the L342A luciferase, D-luciferin gave no signal, while both aminoluciferins gave signal that was >50-fold over background. For the R218K luciferase, D- luciferin signal was ~3-fold over background, but CycLuc1 and CycLuc2 were 40–50 fold brighter still. However, combining the R218K and L342A mutations did not yield synergism in vivo. Although no photon flux above background was observed with D-luciferin for the double mutant, the photon flux was also substantially lower for CycLuc1 and CycLuc2 than for the individual point mutants (Figure S4). Thus, at least in the brain, the double mutant was less useful as a selective luciferase for these substrates compared to L342A or R218K alone. PMC4972182
Mice Transgenic mice Intraperitoneal injection 0.2 mL (10 mg/mL) Single administration To compare the performance of different luciferase systems in the brain PMC10229426
BALB/c mice Dermal and visceral Leishmania infection models Intraperitoneal injection 13 µmol Single injection CycLuc1 showed comparable efficacy at a 20-fold lower dose than D-luciferin, and both substrates can be used to detect parasite levels above 10^6. PMC9781651

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.57mL

0.71mL

0.36mL

17.84mL

3.57mL

1.78mL

35.67mL

7.13mL

3.57mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories